Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.
The pharmacokinetics of intravenous itraconazole (ITC) was studied in dialysis patients. Dialysis had no effect on the half-life and clearance of ITC or OH-ITC. However, dialysis allowed the clearance of hydroxypropyl-beta-cyclodextrin (HP-beta-CD). The area under the concentration-time curve from time zero to infinity (AUC(0- infinity)) for HP-beta-CD administered before dialysis was lower than the AUC(0- infinity) when it was administered after dialysis (P < 0.01). Administration of ITC intravenously just prior to hemodialysis appears to produce adequate systemic exposures of ITC and OH-ITC while allowing dialysis clearance of HP-beta-CD. Studies of multiple administrations are warranted.
Division of Infectious Diseases and Center for the Study of Emerging and Re-emerging Pathogens, University of Texas Health Science Center, Houston, Texas 77030, USA. john.mohr@uth.tmc.edu
John F
JF
Mohr
Kevin W
KW
Finkel
John H
JH
Rex
Jose R
JR
Rodriguez
Gerhard J
GJ
Leitz
Luis
L
Ostrosky-Zeichner
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002138:Calibration; D003505:Cyclodextrins / Q000493:pharmacokinetics; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D017964:Itraconazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007676:Kidney Failure, Chronic / Q000378:metabolism; D006435:Renal Dialysis; D047392:beta-Cyclodextrins
D000935:Antifungal Agents; D003505:Cyclodextrins; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D017964:Itraconazole